Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|March 6, 2006

Applied Clinical Trials

  • Applied Clinical Trials-03-06-2006
  • Volume 0
  • Issue 0

Medidata Solutions to Provide Clinical Data Management Expertise at 18th Annual DIA EuroMeeting

Chief Medical Officer Ed Ikeguchi to Present on UK’s Nationwide EDC Deployment; Senior Director Anne Zielinski to Highlight Data Integration Techniques

NEW YORK, NY – March 1, 2006 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced that Chief Medical Officer Dr. Ed Ikeguchi and newly-appointed Senior Director of Strategic Alliances Anne Zielinski will each be presenting at the 18th Annual DIA EuroMeeting to be held March 6–8, 2006 at Le Palais des Congres in Paris, France.

Ikeguchi's presentation, to be delivered on Wednesday, March 8th at 12:30 p.m., is entitled "The Deployment of Technology Platforms and Electronic Data Capture (EDC) on a National Level: Experience with the National Health Service (NHS) in the United Kingdom." In this seminar, Ikeguchi will present a case study of the UK's government-sponsored effort to improve clinical trials quality and stimulate enrollment through the NHS and the National Cancer Research Network (NCRN). Ikeguchi plans to discuss how standardizing technology as a single platform across an entire nation requires unique considerations for successful implementation.

Zielinski's presentation, "Importing and Exporting Data from EDC – Options and Experiences" on Wednesday, March 8th at 11:00 a.m., will illustrate how increased use of EDC has brought demands for integration of data from various sources. Attendees will learn how data has been integrated, what workflows have been used for integrated data, and how to avoid issues when integrating data.

At this year's show, Medidata Solutions will also be demonstrating its Rave electronic clinical data management solution at booth #55. In addition to showcasing technologies like Rave, the conference will offer attendees an opportunity to learn about the challenges of the revised pharmaceutical legislation and witness the release of the latest developments in important initiatives in Europe.

As one of Medidata's founders and the company's Chief Medical Officer, Ikeguchi focuses on regulatory compliance and 21 CFR Part 11 and is responsible for ensuring defined project goals, objectives, development strategy, resource requirements and scheduling. Prior to forming Medidata Solutions in 2000, Ikeguchi served as assistant professor of clinical urology at Columbia University and held hospital appointments at Columbia Presbyterian, Helen Hayes Hospital and White Plains Hospitals Center. Ikeguchi has served as a clinical investigator in numerous trials sponsored by both the industry and NIH, with experience in technology-based processes related to the pharmaceutical and biotechnology industries. Ikeguchi is a regularly featured presenter at DIA and other industry events.

Zielinski joined Medidata as senior director of strategic alliances in December of 2005. Zielinski had previously served as vice President of strategic alliances at CB Technologies and vice president of business development at WebMD. Zielinski brings 10 years of experience in the EDC industry and is a frequent presenter at key industry events including SCDM and DIA meetings.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.